Catalyst

Slingshot members are tracking this event:

NDA of ARX-04 (sufentanil sublingual tablet 30mcg) for Moderate-to-severe acute pain to be filed 2H 2016

Source Link:
http://news.acelrx.com/phoenix.zhtml?c=241441&p=irol-acelrxnewsArticle&ID=2122200

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ACRX Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Enrollment in the ongoing SAP302 open-label study in the emergency room will be increased, and a new study known as SAP303 is expected to be initiated in the first quarter of 2016 in postoperative patients with moderate-to-severe pain. SAP303 will focus on enrolling patients greater than 40 years of age and will allow for administration of ARX-04 for up to 12 hours. With these modifications, assuming successful completion of the studies, AcelRx anticipates submitting the NDA for ARX-04 in the second half of 2016
http://news.acelrx.c...
Additional Relevant Details Update on Nov 1 2016: Contingent upon FDA acceptance of the NDA for ARX-04 prior to April 1, 2017,  Hercules has agreed to refinance the loan into a 36-month term note with an additional six month interest only period.
http://news.acelrx.c...
Additional Relevant Details Update on Dec 6 2016:- NDA for ARX-04 on track for submission by year-end
http://news.acelrx.c...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Dec 13, 2016
Occurred Source:
http://news.acelrx.com/phoenix.zhtml?c=241441&p=irol-newsArticle&ID=2229186
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda, Arx-04, Moderate-to-severe Acute Pain, 2h 2016, Sufentanil Sublingual Tablet
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.